Synergistic Treatment System for Neurodegenerative Diseases

A comprehensive system integrating Type I PRMT inhibitors with AI, IoT, and blockchain technologies to enhance treatment outcomes for ALS and FTD patients.

The original patent addressed the inhibition of dipeptide repeat proteins, but its limitations included the lack of a comprehensive system for diagnosing, treating, and tracking patient outcomes. The present inventive concept addresses this gap by integrating Type I PRMT inhibitors with advanced technologies to create a more effective and personalized treatment approach.

The system comprises a Type I PRMT inhibitor administration module, an AI-powered diagnostic module for identifying patients with ALS or FTD, and a blockchain-based data storage module for tracking patient treatment outcomes. The system may further include a wearable IoT device for monitoring patient motor neuron activity and transmitting data to the blockchain-based data storage module. The AI-powered predictive model analyzes patient data stored in the blockchain-based data storage module to predict treatment efficacy and identify novel biomarkers for ALS or FTD.

The new claims introduce the synergistic combination of Type I PRMT inhibitors with AI, IoT, and blockchain technologies, which is not obvious from the original patent. The inventive step lies in the integration of these distinct technologies to create a more powerful system for treating neurodegenerative diseases.

Alternative embodiments may include the use of different AI algorithms, IoT devices, or blockchain platforms. Variations may include the integration of additional technologies, such as machine learning or natural language processing, to further enhance the system's capabilities.

The synergistic treatment system has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of neurodegenerative disease treatment and personalized medicine. The system's ability to track patient outcomes and predict treatment efficacy makes it an attractive solution for pharmaceutical companies, hospitals, and research institutions.